Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR: IV AZD0292 in Bronchiectasis with Chronic Pseudomonas Aeruginosa Colonization
jRCT2071260021Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised trial of AZD-0292 in bronchiectasis and Pseudomonal infection (3 arms), sponsored by AstraZeneca. Primary endpoint: Annualized rate of moderate-to-severe pulmonary exacerbations. Started May 2026; status: recruiting.
02
Drugs
AZD-0292
03
Conditions
bronchiectasisPseudomonal infection
Beyond the preview
Go deeper on jRCT2071260021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260021.